Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 9/20 | 0.37 |
| ▸ | HTR2B | P41595 | 8/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 6/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856598 | 0.85 | NPSR1 (0.46) | NPSR1HTR2CHTR2BHTR2A | |
| SCHEMBL2858343 | 0.84 | NPSR1 (0.45) | NPSR1HTR2CHTR2BSLC6A9OPRM1 | |
| SCHEMBL2859277 | 0.78 | SLC6A3 (0.36) | NPSR1HTR2CHTR2BSLC6A9OPRM1 | |
| SCHEMBL2868956 | 0.72 | KCNN4 (0.40) | NPSR1HTR2CHTR2BHTR2AKDM1A | |
| SCHEMBL2869622 | 0.69 | ATM (0.37) | NPSR1OPRM1KCNN4 | |
| SCHEMBL2864855 | 0.69 | KCNN4 (0.37) | NPSR1SLC6A9OPRM1KCNN4 | |
| SCHEMBL2865914 | 0.68 | HTR2C (0.34) | HTR2CHTR2BHTR2A | |
| SCHEMBL2856685 | 0.67 | NPSR1 (0.49) | NPSR1HTR2CHTR2BKCNN4 | |
| SCHEMBL2858344 | 0.67 | HTR2C (0.38) | NPSR1HTR2CHTR2BHTR2ACHRM2 | |
| SCHEMBL28956958 | 0.62 | HTR2C (0.51) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | NPSR1 211/4885HTR2C 264/4885HTR2B 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.